EMA approves combining HLA patient groups in Greenwich LifeSciences trial Jul 16, 2026 07:31AM
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 Jul 16, 2026 07:30AM
EMA clears commercially made GP2 for use in Greenwich LifeSciences trial Jul 9, 2026 06:00AM
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 Jul 9, 2026 06:00AM
Greenwich LifeSciences presents FLAMINGO-01 immune response data Jun 1, 2026 08:16AM
View Older Stories

Jun 1, 2026 08:15AM Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
Jun 1, 2026 06:01AM Greenwich LifeSciences delays Form 10-K filing due to auditor coordination
Jun 1, 2026 06:00AM Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
May 22, 2026 04:30PM Greenwich LifeSciences receives Nasdaq notice for late quarterly filing
May 22, 2026 04:30PM Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Apr 30, 2026 06:01AM Greenwich LifeSciences delays annual filing amid audit completion
Apr 30, 2026 06:00AM Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Apr 23, 2026 06:00AM Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
Apr 22, 2026 05:00PM Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Apr 20, 2026 06:01AM Greenwich LifeSciences presents immunotherapy trial data at cancer meeting
Apr 20, 2026 06:00AM Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
Apr 14, 2026 06:01AM Greenwich LifeSciences reports Q1 cash balance of $10.5 million
Apr 14, 2026 06:00AM Greenwich LifeSciences Provides Update on Financing Strategy
Apr 7, 2026 06:00AM Greenwich LifeSciences files patent claims to expand GLSI-100 eligibility
Apr 7, 2026 06:00AM Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
Mar 19, 2026 06:00AM Greenwich LifeSciences adds City of Hope to breast cancer trial
Mar 19, 2026 06:00AM Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
Mar 18, 2026 06:01AM Greenwich LifeSciences to present FLAMINGO-01 trial data at AACR meeting
Mar 18, 2026 06:00AM Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
Mar 17, 2026 06:02AM Greenwich LifeSciences reports reduced breast cancer recurrence rates
Mar 17, 2026 06:00AM Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01
Mar 16, 2026 06:00AM Greenwich LifeSciences begins using commercial GP2 in breast cancer trial
Mar 16, 2026 06:00AM Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
Mar 3, 2026 06:01AM Greenwich LifeSciences reports 33% increase in FLAMINGO-01 screening rate
Mar 3, 2026 06:00AM Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
Feb 24, 2026 06:01AM Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
Feb 24, 2026 06:00AM Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
Jan 27, 2026 06:00AM Greenwich LifeSciences raises cash balance to $12.5 million through ATM
Jan 27, 2026 06:00AM Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
Jan 22, 2026 06:00AM FDA approves Greenwich LifeSciences commercial GP2 for FLAMINGO-01 trial
Jan 22, 2026 06:00AM Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
Dec 29, 2025 06:01AM Greenwich LifeSciences extends director lock-up to September 2026
Dec 29, 2025 06:00AM Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
Dec 22, 2025 06:00AM Greenwich LifeSciences reports progress on FLAMINGO-01 breast cancer trial
Dec 22, 2025 06:00AM Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
Dec 15, 2025 06:01AM Greenwich LifeSciences reports 80% recurrence reduction in cancer trial
Dec 15, 2025 06:00AM Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
Dec 8, 2025 06:02AM Greenwich LifeSciences completes enrollment in open label arm of phase III trial
Dec 8, 2025 06:00AM Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 
Dec 3, 2025 06:00AM Greenwich LifeSciences screens over 1,000 patients in phase III trial
Dec 3, 2025 06:00AM Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
Oct 9, 2025 06:00AM Greenwich LifeSciences adds Austria to Phase III breast cancer trial
Oct 9, 2025 06:00AM Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
Oct 2, 2025 06:00AM Greenwich LifeSciences expands breast cancer trial to Belgium
Oct 2, 2025 06:00AM Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
Sep 30, 2025 06:01AM Greenwich LifeSciences expands FLAMINGO-01 trial to Portugal
Sep 30, 2025 06:00AM Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
Sep 18, 2025 06:01AM Greenwich LifeSciences expands breast cancer trial to Ireland
Sep 18, 2025 06:00AM Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
Sep 10, 2025 06:00AM Greenwich LifeSciences gets FDA fast track status for breast cancer drug
View Older Stories